In this Phase I , open-label , randomized , three-panel , crossover study ( NCT01619527 ) , healthy volunteers received a single dose of darunavir ( 800 mg ) with cobicistat ( 150 mg ) as either an FDC or as single agents co-administered under fasted ( panel 1 , n = 74 ) or fed ( breakfast , panel 2 , n = 40 ) conditions , or as the FDC under fasted versus fed ( high-fat breakfast ) conditions ( panel 3 , n = 19 ) , with a 7 day washout period between treatments .